Karuna to obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887 Goldfinch Bio assignment estate to ...

Karuna Therapeutics is a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions.

Below is a summary of how these 12 analysts rated Karuna Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater ...

Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older therapies ...

What happened Shares of Karuna Therapeutics (KRTX) were up 14% late Wednesday morning on news regarding the company's lead therapy.

Bristol Myers agrees to buy Boston’s Karuna Therapeutics in a $14 billion deal Karuna has applied for FDA approval of a drug to treat schizophrenia.

Below is a summary of how these 5 analysts rated Karuna Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater ...

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. Read more here.

Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

Karuna Therapeutics' KarXT has shown promising efficacy in phase III studies and has a unique mechanism of action compared to traditional antipsychotics. Find out why KRTX stock is a Buy.

Karuna Therapeutics, Inc. and GFB, LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will obtain global ...